Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice

BACKGROUND: Overall survival (OS) data of osimertinib in pretreated non-small-cell lung cancer (NSCLC) in real-world practice is limited, and treatment benefits for patients not represented in the pivotal trials (ineligible) are unclear. OBJECTIVE: To determine the representativeness of the AURA3 tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Lishi, Smit, Egbert F., de Langen, Adrianus J., van Balen, Dorieke E. M., Beijnen, Jos H., Huitema, Alwin D. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783869/
https://www.ncbi.nlm.nih.gov/pubmed/34894319
http://dx.doi.org/10.1007/s11523-021-00862-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783869/
https://www.ncbi.nlm.nih.gov/pubmed/34894319
http://dx.doi.org/10.1007/s11523-021-00862-x

Ejemplares similares